267 related articles for article (PubMed ID: 26363505)
1. Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators.
Jain AD; Potteti H; Richardson BG; Kingsley L; Luciano JP; Ryuzoji AF; Lee H; Krunic A; Mesecar AD; Reddy SP; Moore TW
Eur J Med Chem; 2015 Oct; 103():252-68. PubMed ID: 26363505
[TBL] [Abstract][Full Text] [Related]
2. Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway.
Richardson BG; Jain AD; Speltz TE; Moore TW
Bioorg Med Chem Lett; 2015 Jun; 25(11):2261-8. PubMed ID: 25937010
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation.
Abed DA; Lee S; Wen X; Ali AR; Mangipudy V; Aleksunes LM; Hu L
Bioorg Med Chem; 2021 Aug; 44():116300. PubMed ID: 34252790
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
Lu MC; Shao HL; Liu T; You QD; Jiang ZY
Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
[TBL] [Abstract][Full Text] [Related]
5. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.
Marcotte D; Zeng W; Hus JC; McKenzie A; Hession C; Jin P; Bergeron C; Lugovskoy A; Enyedy I; Cuervo H; Wang D; Atmanene C; Roecklin D; Vecchi M; Vivat V; Kraemer J; Winkler D; Hong V; Chao J; Lukashev M; Silvian L
Bioorg Med Chem; 2013 Jul; 21(14):4011-9. PubMed ID: 23647822
[TBL] [Abstract][Full Text] [Related]
6. Structure-based molecular hybridization design of Keap1-Nrf2 inhibitors as novel protective agents of acute lung injury.
Zhang L; Xu L; Chen H; Zhang W; Xing C; Qu Z; Yu J; Zhuang C
Eur J Med Chem; 2021 Oct; 222():113599. PubMed ID: 34119834
[TBL] [Abstract][Full Text] [Related]
7. Structural modification of C2-substituents on 1,4-bis(arylsulfonamido)benzene or naphthalene-N,N'-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction.
Lee S; Ali AR; Abed DA; Nguyen MU; Verzi MP; Hu L
Eur J Med Chem; 2024 Feb; 265():116104. PubMed ID: 38159482
[TBL] [Abstract][Full Text] [Related]
8. Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
Richardson BG; Jain AD; Potteti HR; Lazzara PR; David BP; Tamatam CR; Choma E; Skowron K; Dye K; Siddiqui Z; Wang YT; Krunic A; Reddy SP; Moore TW
J Med Chem; 2018 Sep; 61(17):8029-8047. PubMed ID: 30122040
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N'-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction.
Lee S; Abed DA; Nguyen MU; Verzi MP; Hu L
Eur J Med Chem; 2022 Jul; 237():114380. PubMed ID: 35462166
[TBL] [Abstract][Full Text] [Related]
10. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
Uruno A; Motohashi H
Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.
Jiang ZY; Lu MC; Xu LL; Yang TT; Xi MY; Xu XL; Guo XK; Zhang XJ; You QD; Sun HP
J Med Chem; 2014 Mar; 57(6):2736-45. PubMed ID: 24512214
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
14. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
15. Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction.
Abed DA; Lee S; Hu L
Bioorg Med Chem; 2020 Mar; 28(6):115343. PubMed ID: 32046917
[TBL] [Abstract][Full Text] [Related]
16. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1.
Eggler AL; Small E; Hannink M; Mesecar AD
Biochem J; 2009 Jul; 422(1):171-80. PubMed ID: 19489739
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activity.
Yasuda D; Nakajima M; Yuasa A; Obata R; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
Bioorg Med Chem Lett; 2016 Dec; 26(24):5956-5959. PubMed ID: 27839920
[TBL] [Abstract][Full Text] [Related]
19. Control of oxidative stress by the Keap1-Nrf2 pathway.
Stewart JD; Hengstler JG; Bolt HM
Arch Toxicol; 2011 Apr; 85(4):239. PubMed ID: 21431330
[No Abstract] [Full Text] [Related]
20. Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1.
Wu JH; Miao W; Hu LG; Batist G
Chem Biol Drug Des; 2010 May; 75(5):475-80. PubMed ID: 20486933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
